Myelodysplastic Syndrome (MDS) & Chronic Myelomonocytic Leukemia (CMML)

**Higher Risk MDS**
- Naive to Hypomethylating Agents
  - HEMMDS0039
    - Phase III: Macrolimab in Combo w/ Azacitidine vs Azacitidine + Placebo in Treatment-Naive HighRisk MDS
    - PI: Greenberg
    - Sponsor: Gilead Sciences, Inc.
    - Priority 1
  - HEMMDS0043
    - Cellular and Humoral Modulation of Hemopoiesis
    - PI: Greenberg
    - Sponsor: Stanford University

**Lower Risk MDS**
- Failure to respond to Erythropoietic stimulating Agent
  - HEM0056
    - Phase 1b/2 Safety & Efficacy of Enasidenib in MDS/Myelomonocytic Leukemia without IDH2 Mutation
    - PI: Zhang
    - Sponsor: Stanford University
    - Priority 1
  - HEMMDS0043
    - Cellular and Humoral Modulation of Hemopoiesis
    - PI: Greenberg
    - Sponsor: Stanford University
    - Priority 2
  - HEMMDS0042
    - Phase III: INCB000928 Monotherapy in Subjects w/ Anemia Due To Myelodysplastic Syndromes / Multiple Myeloma
    - PI: Shomali
    - Sponsor: Incyte Corporation

**KEY**
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*